Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 568 entries
Sorted by: Best Match Show Resources per page
New cytotoxics and non-cytotoxics in epithelial ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Eisenhauer EA.
PMID: 11240731
Int J Gynecol Cancer. 2000 Jan;10:38-43. doi: 10.1046/j.1525-1438.2000.99509.x.

Several new cytotoxic agents with activity in relapsed ovarian cancer are being combined with paclitaxel plus platinum as the first step to assess their impact in randomized trials against the standard treatment. These include topotecan, gemcitabine, epirubicin, and liposomal...

Cite
Eisenhauer EA. New cytotoxics and non-cytotoxics in epithelial ovarian cancer. Int J Gynecol Cancer. 2000;10:38-43doi: 10.1046/j.1525-1438.2000.99509.x.
Eisenhauer, E. A. (2000). New cytotoxics and non-cytotoxics in epithelial ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 1038-43. https://doi.org/10.1046/j.1525-1438.2000.99509.x
Eisenhauer, E. A.. "New cytotoxics and non-cytotoxics in epithelial ovarian cancer." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society vol. 10 (2000): 38-43. doi: https://doi.org/10.1046/j.1525-1438.2000.99509.x
Eisenhauer EA. New cytotoxics and non-cytotoxics in epithelial ovarian cancer. Int J Gynecol Cancer. 2000 Jan;10:38-43. doi: 10.1046/j.1525-1438.2000.99509.x. PMID: 11240731.
Copy Download .nbib Format: NLM
Prospective Randomized Study of Cyclophosphamide, Epirubicin, and 5-Fluorouracil versus Cyclophosphamide, Adriamycin, and 5-Fluorouracil in Advanced or Recurrent Breast Cancer.

Breast cancer (Tokyo, Japan)

Kobayashi T, Koyama H, Oka T, Yasumura T, Kan N, Takatsuka Y, Noguchi M, Morimoto K, Suzuki T, Tobe T, Mori T.
PMID: 11091688
Breast Cancer. 1999 Jan 25;6(1):37-42. doi: 10.1007/BF02966904.

BACKGROUND: Treatment with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF), a widely used, potent regimen is sometimes restricted by the myelotoxicityand myocardiotoxicity of adriamycin (ADR). In a prospective randomized controlled study of patients with advanced or recurrent breast cancer, the efficacy...

Cite
Kobayashi T, Koyama H, Oka T, et al. Prospective Randomized Study of Cyclophosphamide, Epirubicin, and 5-Fluorouracil versus Cyclophosphamide, Adriamycin, and 5-Fluorouracil in Advanced or Recurrent Breast Cancer. Breast Cancer. 1999;6(1):37-42doi: 10.1007/BF02966904.
Kobayashi, T., Koyama, H., Oka, T., Yasumura, T., Kan, N., Takatsuka, Y., Noguchi, M., Morimoto, K., Suzuki, T., Tobe, T., & Mori, T. (1999). Prospective Randomized Study of Cyclophosphamide, Epirubicin, and 5-Fluorouracil versus Cyclophosphamide, Adriamycin, and 5-Fluorouracil in Advanced or Recurrent Breast Cancer. Breast cancer (Tokyo, Japan), 6(1), 37-42. https://doi.org/10.1007/BF02966904
Kobayashi, et al. "Prospective Randomized Study of Cyclophosphamide, Epirubicin, and 5-Fluorouracil versus Cyclophosphamide, Adriamycin, and 5-Fluorouracil in Advanced or Recurrent Breast Cancer." Breast cancer (Tokyo, Japan) vol. 6,1 (1999): 37-42. doi: https://doi.org/10.1007/BF02966904
Kobayashi T, Koyama H, Oka T, Yasumura T, Kan N, Takatsuka Y, Noguchi M, Morimoto K, Suzuki T, Tobe T, Mori T. Prospective Randomized Study of Cyclophosphamide, Epirubicin, and 5-Fluorouracil versus Cyclophosphamide, Adriamycin, and 5-Fluorouracil in Advanced or Recurrent Breast Cancer. Breast Cancer. 1999 Jan 25;6(1):37-42. doi: 10.1007/BF02966904. PMID: 11091688.
Copy Download .nbib Format: NLM
Evolution of preoperative and postoperative therapies in the management of localized gastroesophageal cancers.

Gastrointestinal cancer research : GCR

Karpeh MS.
PMID: 19343158
Gastrointest Cancer Res. 2007 Mar;1(2):S4-9.

Recent changes in the epidemiology of gastroesophageal cancers in the United States and many parts of Europe require reassessment of traditional surgical and adjuvant treatment approaches to these tumors. Careful preoperative staging and classification aid in the selection of...

Cite
Karpeh MS. Evolution of preoperative and postoperative therapies in the management of localized gastroesophageal cancers. Gastrointest Cancer Res. 2007;1(2):S4-9
Karpeh, M. S. (2007). Evolution of preoperative and postoperative therapies in the management of localized gastroesophageal cancers. Gastrointestinal cancer research : GCR, 1(2), S4-9.
Karpeh, Martin S. "Evolution of preoperative and postoperative therapies in the management of localized gastroesophageal cancers." Gastrointestinal cancer research : GCR vol. 1,2 (2007): S4-9.
Karpeh MS. Evolution of preoperative and postoperative therapies in the management of localized gastroesophageal cancers. Gastrointest Cancer Res. 2007 Mar;1(2):S4-9. PMID: 19343158; PMCID: PMC2661561.
Copy Download .nbib Format: NLM
Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients.

World journal of gastrointestinal oncology

Sakuramoto S, Yamashita K, Watanabe M.
PMID: 21160774
World J Gastrointest Oncol. 2009 Oct 15;1(1):47-54. doi: 10.4251/wjgo.v1.i1.47.

With the increase in average life expectancy, the rate of occurrence of gastric cancer in elderly patients is also rising. While many clinical trials have been conducted to examine the effect of chemotherapy treatment on gastric cancer, age limits...

Cite
Sakuramoto S, Yamashita K, Watanabe M. Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients. World J Gastrointest Oncol. 2009;1(1):47-54doi: 10.4251/wjgo.v1.i1.47.
Sakuramoto, S., Yamashita, K., & Watanabe, M. (2009). Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients. World journal of gastrointestinal oncology, 1(1), 47-54. https://doi.org/10.4251/wjgo.v1.i1.47
Sakuramoto, Shinichi, et al. "Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients." World journal of gastrointestinal oncology vol. 1,1 (2009): 47-54. doi: https://doi.org/10.4251/wjgo.v1.i1.47
Sakuramoto S, Yamashita K, Watanabe M. Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients. World J Gastrointest Oncol. 2009 Oct 15;1(1):47-54. doi: 10.4251/wjgo.v1.i1.47. PMID: 21160774; PMCID: PMC2999089.
Copy Download .nbib Format: NLM
Effect of Supplementation of Tanshinone IIA and Sodium Tanshinone IIA Sulfonate on the Anticancer Effect of Epirubicin: An In Vitro Study.

Evidence-based complementary and alternative medicine : eCAM

Chan SE, Lai HW, Su CC, Kuo SJ, Chien SY, Lin HY, Chen DR.
PMID: 21716682
Evid Based Complement Alternat Med. 2011;2011:841564. doi: 10.1155/2011/841564. Epub 2011 May 24.

Tanshinone IIA (Tan IIA) and sodium tanshinone IIA sulfonate (STS) were found to have protective effects on cardiomyocyte against adriamycin-induced damage and may be used clinically. It is unclear whether the supplementation of STS or Tan IIA would affect...

Cite
Chan SE, Lai HW, Su CC, et al. Effect of Supplementation of Tanshinone IIA and Sodium Tanshinone IIA Sulfonate on the Anticancer Effect of Epirubicin: An In Vitro Study. Evid Based Complement Alternat Med. 2011;2011:841564doi: 10.1155/2011/841564.
Chan, S. E., Lai, H. W., Su, C. C., Kuo, S. J., Chien, S. Y., Lin, H. Y., & Chen, D. R. (2011). Effect of Supplementation of Tanshinone IIA and Sodium Tanshinone IIA Sulfonate on the Anticancer Effect of Epirubicin: An In Vitro Study. Evidence-based complementary and alternative medicine : eCAM, 2011841564. https://doi.org/10.1155/2011/841564
Chan, Szu-Erh, et al. "Effect of Supplementation of Tanshinone IIA and Sodium Tanshinone IIA Sulfonate on the Anticancer Effect of Epirubicin: An In Vitro Study." Evidence-based complementary and alternative medicine : eCAM vol. 2011 (2011): 841564. doi: https://doi.org/10.1155/2011/841564
Chan SE, Lai HW, Su CC, Kuo SJ, Chien SY, Lin HY, Chen DR. Effect of Supplementation of Tanshinone IIA and Sodium Tanshinone IIA Sulfonate on the Anticancer Effect of Epirubicin: An In Vitro Study. Evid Based Complement Alternat Med. 2011;2011:841564. doi: 10.1155/2011/841564. Epub 2011 May 24. PMID: 21716682; PMCID: PMC3118485.
Copy Download .nbib Format: NLM
T cell-prolymphocytic leukemia detected in a patient of breast cancer at the time of recurrence: a case report.

Cases journal

Singhal M, Raina V, Gupta R, Das P.
PMID: 20076807
Cases J. 2010 Jan 04;3:4. doi: 10.1186/1757-1626-3-4.

INTRODUCTION: Therapy related second malignancy of the hematological system is small but real risk after adjuvant chemotherapy for breast cancer. It includes acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); however T-cell prolymphocytic leukemia (T-PLL) has not been described...

Cite
Singhal M, Raina V, Gupta R, et al. T cell-prolymphocytic leukemia detected in a patient of breast cancer at the time of recurrence: a case report. Cases J. 2010;3:4doi: 10.1186/1757-1626-3-4.
Singhal, M., Raina, V., Gupta, R., & Das, P. (2010). T cell-prolymphocytic leukemia detected in a patient of breast cancer at the time of recurrence: a case report. Cases journal, 34. https://doi.org/10.1186/1757-1626-3-4
Singhal, Manish, et al. "T cell-prolymphocytic leukemia detected in a patient of breast cancer at the time of recurrence: a case report." Cases journal vol. 3 (2010): 4. doi: https://doi.org/10.1186/1757-1626-3-4
Singhal M, Raina V, Gupta R, Das P. T cell-prolymphocytic leukemia detected in a patient of breast cancer at the time of recurrence: a case report. Cases J. 2010 Jan 04;3:4. doi: 10.1186/1757-1626-3-4. PMID: 20076807; PMCID: PMC2806858.
Copy Download .nbib Format: NLM
Neoadjuvant docetaxel and epirubicin in large and locally advanced breast cancer: kuwait cancer control centre experience.

Journal of the Egyptian National Cancer Institute

Alawadi SA, Delvadiya M, Fayaz S, Khalid H.
PMID: 20424658
J Egypt Natl Canc Inst. 2008 Sep;20(3):271-80.

PURPOSE: To evaluate the efficacy of neoadjuvant (NA) docetaxel (DOC) and Epirubicin (EPI) as a part of multimodality treatment of large and locally advanced breast cancer.PATIENTS AND METHODS: Patients with large or locally advanced breast cancer received four cycles...

Cite
Alawadi SA, Delvadiya M, Fayaz S, et al. Neoadjuvant docetaxel and epirubicin in large and locally advanced breast cancer: kuwait cancer control centre experience. J Egypt Natl Canc Inst. 2008;20(3):271-80
Alawadi, S. A., Delvadiya, M., Fayaz, S., & Khalid, H. (2008). Neoadjuvant docetaxel and epirubicin in large and locally advanced breast cancer: kuwait cancer control centre experience. Journal of the Egyptian National Cancer Institute, 20(3), 271-80.
Alawadi, Shafika A A, et al. "Neoadjuvant docetaxel and epirubicin in large and locally advanced breast cancer: kuwait cancer control centre experience." Journal of the Egyptian National Cancer Institute vol. 20,3 (2008): 271-80.
Alawadi SA, Delvadiya M, Fayaz S, Khalid H. Neoadjuvant docetaxel and epirubicin in large and locally advanced breast cancer: kuwait cancer control centre experience. J Egypt Natl Canc Inst. 2008 Sep;20(3):271-80. PMID: 20424658.
Copy Download .nbib Format: NLM
New prospects for the treatment of germ-cell tumours.

Expert opinion on investigational drugs

Droz JP, Culine S.
PMID: 15992021
Expert Opin Investig Drugs. 1998 Jul;7(7):1139-57. doi: 10.1517/13543784.7.7.1139.

Germ-cell tumours are rare tumours of testicular, ovarian and extra-gonadal origins. Most are curable by cisplatin-based chemotherapy regimens and surgery. Treatment strategy is based on risk factor assessment. The standard cytotoxic drugs used for the treatment of this disease...

Cite
Droz JP, Culine S. New prospects for the treatment of germ-cell tumours. Expert Opin Investig Drugs. 1998;7(7):1139-57doi: 10.1517/13543784.7.7.1139.
Droz, J. P., & Culine, S. (1998). New prospects for the treatment of germ-cell tumours. Expert opinion on investigational drugs, 7(7), 1139-57. https://doi.org/10.1517/13543784.7.7.1139
Droz, J P, and Culine, S. "New prospects for the treatment of germ-cell tumours." Expert opinion on investigational drugs vol. 7,7 (1998): 1139-57. doi: https://doi.org/10.1517/13543784.7.7.1139
Droz JP, Culine S. New prospects for the treatment of germ-cell tumours. Expert Opin Investig Drugs. 1998 Jul;7(7):1139-57. doi: 10.1517/13543784.7.7.1139. PMID: 15992021.
Copy Download .nbib Format: NLM
Rare metastatic prostatic malignancy: A case report and approach to management.

Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology

Krishna MV, Prabhash K, Noronha V, Menon S, Dua SG, Rangarajan V, Tangaonkar HB.
PMID: 22563161
Indian J Med Paediatr Oncol. 2011 Oct;32(4):233-7. doi: 10.4103/0971-5851.95149.

We present a patient with metastatic leiomyosarcoma of the prostate who achieved complete response with chemotherapy. A 70 years old male patient presented with urinary tract symptoms and a prostatic mass. After having been treated as carcinoma prostate, he...

Cite
Krishna MV, Prabhash K, Noronha V, et al. Rare metastatic prostatic malignancy: A case report and approach to management. Indian J Med Paediatr Oncol. 2011;32(4):233-7doi: 10.4103/0971-5851.95149.
Krishna, M. V., Prabhash, K., Noronha, V., Menon, S., Dua, S. G., Rangarajan, V., & Tangaonkar, H. B. (2011). Rare metastatic prostatic malignancy: A case report and approach to management. Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology, 32(4), 233-7. https://doi.org/10.4103/0971-5851.95149
Krishna, M Vamshi, et al. "Rare metastatic prostatic malignancy: A case report and approach to management." Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology vol. 32,4 (2011): 233-7. doi: https://doi.org/10.4103/0971-5851.95149
Krishna MV, Prabhash K, Noronha V, Menon S, Dua SG, Rangarajan V, Tangaonkar HB. Rare metastatic prostatic malignancy: A case report and approach to management. Indian J Med Paediatr Oncol. 2011 Oct;32(4):233-7. doi: 10.4103/0971-5851.95149. PMID: 22563161; PMCID: PMC3343254.
Copy Download .nbib Format: NLM
The use of peripheral-blood hematopoietic progenitors mobilized with standard-dose chemotherapy plus granulocyte-colony-stimulating factor to support multicyclic dose-intensive chemotherapy for advanced breast-cancer.

Oncology reports

Danova M, Rosti V, Mora O, Perotti C, Cazzola M, Riccardi A, Ascari E.
PMID: 21597856
Oncol Rep. 1995 Nov;2(6):1075-8. doi: 10.3892/or.2.6.1075.

This study was aimed at determining: (a) the degree of mobilization of peripheral blood hematopoietic progenitors (PBSC) induced by a single course of standard-dose chemotherapy (CT) followed by G-CSF and the feasibility and safety of the administration of multiple...

Cite
Danova M, Rosti V, Mora O, et al. The use of peripheral-blood hematopoietic progenitors mobilized with standard-dose chemotherapy plus granulocyte-colony-stimulating factor to support multicyclic dose-intensive chemotherapy for advanced breast-cancer. Oncol Rep. 1995;2(6):1075-8doi: 10.3892/or.2.6.1075.
Danova, M., Rosti, V., Mora, O., Perotti, C., Cazzola, M., Riccardi, A., & Ascari, E. (1995). The use of peripheral-blood hematopoietic progenitors mobilized with standard-dose chemotherapy plus granulocyte-colony-stimulating factor to support multicyclic dose-intensive chemotherapy for advanced breast-cancer. Oncology reports, 2(6), 1075-8. https://doi.org/10.3892/or.2.6.1075
Danova, M, et al. "The use of peripheral-blood hematopoietic progenitors mobilized with standard-dose chemotherapy plus granulocyte-colony-stimulating factor to support multicyclic dose-intensive chemotherapy for advanced breast-cancer." Oncology reports vol. 2,6 (1995): 1075-8. doi: https://doi.org/10.3892/or.2.6.1075
Danova M, Rosti V, Mora O, Perotti C, Cazzola M, Riccardi A, Ascari E. The use of peripheral-blood hematopoietic progenitors mobilized with standard-dose chemotherapy plus granulocyte-colony-stimulating factor to support multicyclic dose-intensive chemotherapy for advanced breast-cancer. Oncol Rep. 1995 Nov;2(6):1075-8. doi: 10.3892/or.2.6.1075. PMID: 21597856.
Copy Download .nbib Format: NLM
Words of wisdom. Re: Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Sylvester RJ, Brausi MA, Kirkels WJ, et al.

European urology

Lamm DL.
PMID: 21531192
Eur Urol. 2011 Jun;59(6):1065. doi: 10.1016/j.eururo.2011.03.040.

No abstract available.

Cite
Lamm DL. Words of wisdom. Re: Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Sylvester RJ, Brausi MA, Kirkels WJ, et al. Eur Urol. 2011;59(6):1065doi: 10.1016/j.eururo.2011.03.040.
Lamm, D. L. (2011). Words of wisdom. Re: Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Sylvester RJ, Brausi MA, Kirkels WJ, et al. European urology, 59(6), 1065. https://doi.org/10.1016/j.eururo.2011.03.040
Lamm, Donald L. "Words of wisdom. Re: Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Sylvester RJ, Brausi MA, Kirkels WJ, et al." European urology vol. 59,6 (2011): 1065. doi: https://doi.org/10.1016/j.eururo.2011.03.040
Lamm DL. Words of wisdom. Re: Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Sylvester RJ, Brausi MA, Kirkels WJ, et al. Eur Urol. 2011 Jun;59(6):1065. doi: 10.1016/j.eururo.2011.03.040. PMID: 21531192.
Copy Download .nbib Format: NLM
Fec (Fluorouracil, epirubicin, cyclophosphamide) plus granulocyte macrophage-colony-stimulating factor (gm-csf) in advanced or inflammatory breast-cancer - a dose-finding study.

International journal of oncology

Lorusso V, Tatulli C, Berardi F, Brandi M, Demitrio A, Cataldi A, Fioretto A, Sarcina R, Schittulli F, Delena M.
PMID: 21573352
Int J Oncol. 1993 Aug;3(2):223-8. doi: 10.3892/ijo.3.2.223.

Seven patients with inflammatory and 11 with metastatic breast cancer were treated with high dose FEC chemotherapy plus GM-CSF; 5-fluorouracil and cyclophosphamide were administered at 500 mg/m2/iv/day 1, epirubicin at three dose levels: 100 mg, 120 mg and 140...

Cite
Lorusso V, Tatulli C, Berardi F, et al. Fec (Fluorouracil, epirubicin, cyclophosphamide) plus granulocyte macrophage-colony-stimulating factor (gm-csf) in advanced or inflammatory breast-cancer - a dose-finding study. Int J Oncol. 1993;3(2):223-8doi: 10.3892/ijo.3.2.223.
Lorusso, V., Tatulli, C., Berardi, F., Brandi, M., Demitrio, A., Cataldi, A., Fioretto, A., Sarcina, R., Schittulli, F., & Delena, M. (1993). Fec (Fluorouracil, epirubicin, cyclophosphamide) plus granulocyte macrophage-colony-stimulating factor (gm-csf) in advanced or inflammatory breast-cancer - a dose-finding study. International journal of oncology, 3(2), 223-8. https://doi.org/10.3892/ijo.3.2.223
Lorusso, V, et al. "Fec (Fluorouracil, epirubicin, cyclophosphamide) plus granulocyte macrophage-colony-stimulating factor (gm-csf) in advanced or inflammatory breast-cancer - a dose-finding study." International journal of oncology vol. 3,2 (1993): 223-8. doi: https://doi.org/10.3892/ijo.3.2.223
Lorusso V, Tatulli C, Berardi F, Brandi M, Demitrio A, Cataldi A, Fioretto A, Sarcina R, Schittulli F, Delena M. Fec (Fluorouracil, epirubicin, cyclophosphamide) plus granulocyte macrophage-colony-stimulating factor (gm-csf) in advanced or inflammatory breast-cancer - a dose-finding study. Int J Oncol. 1993 Aug;3(2):223-8. doi: 10.3892/ijo.3.2.223. PMID: 21573352.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 568 entries